Base Therapeutics is at the forefront of advancing gene editing technologies, particularly through its proprietary AccuBase® base editing system. This innovative platform allows for highly efficient gene editing both in vitro and in vivo, with a focus on minimizing off-target effects, which is a significant concern in gene therapy. The company has also developed an enhanced prime editing technology known as ePE, which further expands its capabilities in precise genetic modifications. Base Therapeutics is committed to addressing critical challenges in the field, particularly in the development of its BASE-NK and BEAT-CART product pipelines, which aim to improve the efficacy and safety of immune cell therapies.

In addition to its core technologies, Base Therapeutics has demonstrated impressive results in expanding and genetically modifying natural killer (NK) cells, achieving transduction efficiencies that are significantly higher than industry standards. The company’s BASE-NK products have successfully completed proof-of-concept studies and have submitted Investigational New Drug (IND) applications in both China and the U.S. Furthermore, Base Therapeutics is actively pursuing strategic partnerships to broaden the application of its AccuBase® technology across various sectors, including human disease treatment, agriculture, and fundamental research, thereby enhancing the potential for precision gene editing to contribute to a healthier and more sustainable world.

China

On August 20, 2024, Base Therapeutics announced that its AccuBase® base editor has officially received authorization for two patents from the United States Patent and Trademark Office (USPTO). This marks that both of Base Therapeutics' AccuBase® technologies have secured patent protection in China and overseas markets. Base Therapeutics' strategic positioning in the gene editing field is at the forefront internationally, making it one of the biopharmaceutical companies with the most authorizations domestically and abroad.

Floor 1, Building 23, No. 200 Jinsu Road, No. 700 Jiqiao Road, Pudong New Area, Shanghai, China

Base Therapeutics

Company Details